Financials Cybin Inc.

Equities

CYBN

CA23256X1006

Biotechnology & Medical Research

Market Closed - Nyse 04:00:00 2024-05-21 pm EDT 5-day change 1st Jan Change
0.3549 USD +1.11% Intraday chart for Cybin Inc. +3.83% -13.44%

Valuation

Fiscal Period: March 2021 2022 2023 2024 2025 2026
Capitalization 1 205.5 177.2 102.4 363.1 - -
Enterprise Value (EV) 1 141.4 123.5 85.8 192.7 237.3 185.2
P/E ratio -4.1 x -2.55 x -2 x -2.02 x -3.47 x -4.48 x
Yield - - - - - -
Capitalization / Revenue 238 x - - - - -
EV / Revenue 164 x - - - - -
EV / EBITDA -7.38 x -2.71 x -1.84 x -2.86 x -4.15 x -2.73 x
EV / FCF -7.38 x -2.73 x -1.8 x -3.17 x -4.14 x -2.51 x
FCF Yield -13.5% -36.7% -55.4% -31.5% -24.1% -39.9%
Price to Book 1.52 x 2.24 x 2 x 0.82 x 1.99 x 1.65 x
Nbr of stocks (in thousands) 156,782 173,458 196,913 760,053 - -
Reference price 2 1.310 1.021 0.5202 0.4777 0.4777 0.4777
Announcement Date 6/28/21 6/22/22 6/27/23 - - -
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - 0.864 - - - - -
EBITDA 1 - -19.17 -45.64 -46.58 -67.35 -57.15 -67.95
EBIT 1 - -32.28 -63.84 -51.52 -68.91 -67.88 -79.36
Operating Margin - -3,736.11% - - - - -
Earnings before Tax (EBT) 1 - -32.22 -67.63 -47.49 -74.69 -70.41 -77.47
Net income 1 -0.8098 -32.22 -67.63 -47.49 -74.54 -70.41 -84.23
Net margin - -3,729.17% - - - - -
EPS 2 - -0.3200 -0.4000 -0.2600 -0.2367 -0.1375 -0.1067
Free Cash Flow 1 - -19.16 -45.31 -47.57 -60.75 -57.26 -73.84
FCF margin - -2,217.82% - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 11/9/20 6/28/21 6/22/22 6/27/23 - - -
1CAD in Million2CAD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3 2025 Q4
Net sales 1 - - - - - - - - - - - - - - -
EBITDA 1 -11.61 -11.95 -12.95 -11.19 -11.2 -11.04 -13.15 -12.64 -13.84 -26.88 -13.95 -13.8 -13.9 -14.2 -14.3
EBIT 1 -17.11 -16.46 -16.34 -13.4 -12.33 -12.09 -13.7 -12.71 -13.91 -27.02 -17.99 -14 -14.1 -14.4 -14.5
Operating Margin - - - - - - - - - - - - - - -
Earnings before Tax (EBT) 1 -17.61 -17.21 -18.1 -13.06 -9.973 -10.74 -13.72 -14.51 -11.89 -30.33 -17.97 -12.5 -12.7 -13.1 -13.3
Net income 1 -17.61 -17.21 -18.1 -13.06 -10 -10.74 -13.72 -14.51 -11.89 -30.33 -18.35 -12.5 -12.7 -13.1 -13.3
Net margin - - - - - - - - - - - - - - -
EPS 2 -0.1100 -0.1000 -0.1000 -0.0700 -0.0600 -0.0600 -0.0700 -0.0700 -0.0500 -0.0900 -0.0417 -0.0100 -0.0100 -0.0200 -0.0200
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/15/21 2/10/22 6/22/22 8/8/22 11/14/22 2/14/23 6/27/23 8/14/23 11/14/23 2/14/24 - - - - -
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: March 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - -
Net Cash position 1 - 64 53.6 16.6 170 126 178
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 1 - -19.2 -45.3 -47.6 -60.8 -57.3 -73.8
ROE (net income / shareholders' equity) - -73.6% -79.2% -76.4% -46.4% -22.4% -26.3%
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share 2 - 0.8600 0.4600 0.2600 0.5800 0.2400 0.2900
Cash Flow per Share 2 - -0.1900 -0.2700 -0.2600 -0.1400 -0.0500 -0.0500
Capex 1 - 0.14 0.11 0.14 0.04 3.01 5.89
Capex / Sales - 15.62% - - - - -
Announcement Date 11/9/20 6/28/21 6/22/22 6/27/23 - - -
1CAD in Million2CAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0.4777 CAD
Average target price
6.089 CAD
Spread / Average Target
+1,174.77%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW